Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral semaglutide versus placebo in children and adolescents with type 2 diabetes on metformin and/or basal insulin
NL-OMON54032Phase 3Recruiting
- Sponsor
- Novo Nordisk
- Start
- Jul 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Oral semaglutide + background therapy with Placebo + background therapy (2 arms). Primary endpoint: Change from baseline to week 26 in HbA1c. Started Jul 2021; status: recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON54032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54032.